Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.
The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.
Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.
shanghai microport endovascular medtech(group)co.,ltd. net profit increased by more than 44% in the first half of the year. Can going overseas alleviate the impact of Castor's price reduction?
1. Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. accelerates its 'going global' strategy, with overseas revenue increasing by 67.04% in the first half of the year, accounting for 8.84% of the total revenue; 2. The reporter from the 'Star Market Daily' asked employees of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. whether they would correspondingly adjust the prices facing dealers in response to the significant price reduction of Castor brackets' terminal. The other party refused to disclose more information, citing 'inconvenience to reply.'
beijing wantai biological pharmacy enterprise's application for the listing of the nine-valent HPV vaccine has been accepted, but the stock price is "handsome for only three seconds"?
① Beijing Wantai Biological Pharmacy Enterprise has received the acceptance notice from the Drug Evaluation Center of the National Medical Products Administration for the application of the marketing authorization of its nine-valent HPV vaccine. ② The stock price of Beijing Wantai Biological Pharmacy Enterprise rose sharply this afternoon, but quickly fell back. As of the close of today, the increase was 3.9%. ③ In addition, Beijing Wantai Biological Pharmacy Enterprise is still facing fierce competition from its rivals in the field of nine-valent HPV vaccines.
Express News | Biomedical stocks in Hong Kong continued to rise in the afternoon, with Wuxi Bio up nearly 7%, Wuxi Apptec and Wuxi Huijian up more than 5%, Innocare and Beigene up more than 4%.
High inventory coupled with industry pressure, Chongqing Taiji Industry's H1 revenue and net profit both declined. | Interpretation of financial statements.
In the first half of this year, chongqing taiji industry's net profit was 0.495 billion yuan, a year-on-year decrease of 12.51%; The company stated that the poor performance in the first half of the year was mainly due to the high base of the same period last year and the high social inventory of some products.